Cargando…

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine that has been implicated in a variety of rheumatic and inflammatory diseases. New understanding of the importance of TNF-α in the pathophysiology of rheumatoid arthritis and Crohn's disease led to the development of a new class of...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kalden, Joachim R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2002
Materias:	Supplement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238220/ https://www.ncbi.nlm.nih.gov/pubmed/12110156 http://dx.doi.org/10.1186/ar552

Ejemplares similares

Leishmaniasis, Autoimmune Rheumatic Disease, and Anti–Tumor Necrosis Factor Therapy, Europe
por: Xynos, Ioannis D., et al.
Publicado: (2009)

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
por: Aikawa, Nadia Emi, et al.
Publicado: (2011)

Standardization of Epidemiological Surveillance of Rheumatic Heart Disease( )
por: Scheel, Amy, et al.
Publicado: (2022)

Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
por: Leipe, Jan, et al.
Publicado: (2019)

Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
por: Kostine, Marie, et al.
Publicado: (2019)

Anti-TNF therapy: what have we learned in 12 years?
por: Kalden, Joachim R
Publicado: (2011)

Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Engel-Nitz, Nicole M., et al.
Publicado: (2015)

Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
por: Steven, Neil M, et al.
Publicado: (2019)

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study
por: Okihiro, Alexandra, et al.
Publicado: (2018)

Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
por: Rao, Vamshi K., et al.
Publicado: (2018)

Trends in the Management of Type 2 Diabetes: An Emerging Role for Insulin
por: Braunstein, Seth N., et al.
Publicado: (2005)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
por: Park, Jihye, et al.
Publicado: (2018)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Standardization of Epidemiological Surveillance of Acute Rheumatic Fever( )
por: Scheel, Amy, et al.
Publicado: (2022)

Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor
por: Abdulkader, Omer Ahmad Fatheddin, et al.
Publicado: (2016)

Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple Sclerosis
por: Bandari, Daniel S., et al.
Publicado: (2012)

Obstacles to Anti-CD4 Therapy in Rheumatoid Arthritis
por: Kalden, Joachim R, et al.
Publicado: (2000)

An Evidence-Based Approach: The Emerging Role of Renal Protection in Hypertension; A Focus on Clinical and Economic Factors That Impact Formulary Decision Making
por: Rodby, Roger A., et al.
Publicado: (2004)

Predicting the future of anti-tumor necrosis factor therapy
por: Verweij, Cornelis L
Publicado: (2009)

Anticipating the Future: How the Emergence of Innovative Biologic Agents Impacts Benefit Design, Utilization, and Provider Relations
por: Lipsy, Robert J., et al.
Publicado: (2004)

Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis
por: Wood, Patrick R, et al.
Publicado: (2018)

SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis
por: Lerner, Emily, et al.
Publicado: (2021)

Regulation of myeloid cell function and MHC class II expression by tumor necrosis factor
por: Mueller, RB, et al.
Publicado: (2005)

Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015)

Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn’s Disease
por: Bafutto, Mauro, et al.
Publicado: (2020)

The potential role of 'non-rheumatic’ therapies in rheumatic disease
por: Massarotti, Elena M, et al.
Publicado: (2013)

Alopecia secondary to anti-tumor necrosis factor-alpha therapy()
por: Ribeiro, Lara Beatriz Prata, et al.
Publicado: (2015)

Computational analysis to investigate the anti-rheumatic potential of plant-based small molecule inhibitor targeting tumor necrosis factor α
por: Rehman, Sanaya, et al.
Publicado: (2023)

Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
por: Ye, Byong Duk
Publicado: (2014)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
por: Kotze, Paulo Gustavo, et al.
Publicado: (2017)

Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
por: Thurlapati, Aswani, et al.
Publicado: (2021)

Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Estimates of HIV burden in emergencies
por: Lowicki-Zucca, M, et al.
Publicado: (2008)

The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes
por: Triplitt, Curtis, et al.
Publicado: (2007)

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
por: Winthrop, Kevin L., et al.
Publicado: (2009)

Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis
por: Ramirez, J, et al.
Publicado: (2010)

Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
por: Bakri, Sophie J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ibmpg9pj5gostg7c628oj188e